SIRT Sierra Natl BK Tehachapi Calif (MM)

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Chief Executive Officer and Vice Chair Christoph Westphal, M.D., Ph.D. will give the keynote address at the annual Charit� Hospital/University of Berlin scientific symposium. The talk will be on Tuesday, January 22 at 5:00 pm GMT. �It was an honor to be invited by Professor Detlev Ganten, CEO of the Charit� Medical School, to present at their annual scientific symposium,� said Westphal. �The Charit� is one of the most famous hospitals in Continental Europe and is surrounded by extremely talented scientists. My talk will focus on developing new therapies from academic discoveries, with particular emphasis on creating drugs that target the sirtuins, genes associated with aging.� �Christoph has demonstrated visionary leadership and a proven ability to take cutting-edge research from academic medical centers into the biotech sector, first with Alnylam and RNA interference where key discoveries were made in Germany, and now with Sirtris regarding diseases of aging,� said Professor and Charit� Chief Executive Officer Detlev Ganten. The annual Charit� symposium is attended by more than 500 scientists, doctors, and politicians, including the leadership of the biomedical sector in Germany. Speaking at this year�s event are Dr. Ganten, Senator Juergen Zoellner, and Dr. Westphal. The event is hosted by Johanna Quandt and the Quandt family, owners of BMW and longtime lead supporters of the Charit� Hospital. The Charit� was recently ranked the top university medical school in Germany, as well as the top German medical school in impact and grant money. It has an annual budget of $1.5 billion USD. The medical school has been home to eight Nobel Laureates, including Robert Koch, Otto Warburg, and Rudolf Virchow, as well as many of the leading biomedical scientists in Germany. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the potential therapeutic effects of SIRT1 activators for diseases of aging, the progress and results of pre-clinical and clinical studies of SIRT1 activators, development of first-in-class therapeutics that modulate sirtuins, and the potential of sirtuin modulators to receive regulatory approval. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company's product candidates will be safe or effective, or receive regulatory approval, the possibility that results of pre-clinical studies are not necessarily predictive of clinical trial results, the Company's potential inability to initiate and complete pre-clinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.